Treatment goals for psoriasis: Should PASI 90 become the standard of care?;Objetivos terapéuticos en la psoriasis: ¿debería ser la respuesta PASI90 la norma asistencial?

Actas Dermo-Sifiliograficas

Volumn 106, Issue 3, 2015, Pages 155-157

  Torres, T ^a,b   Puig, L ^c,d  

^a Institute of Biomedical Sciences Abel Salazar   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BRODALUMAB; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 17; IXEKIZUMAB; METHOTREXATE; SECUKINUMAB; EFALIZUMAB; USTEKINUMAB;

DISEASE SEVERITY; EUROPEAN; GOLD STANDARD; HEALTH CARE QUALITY; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; NOTE; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; ARTICLE; BIOLOGICAL THERAPY; DERMATOLOGY LIFE QUALITY INDEX; MINIMAL CLINICALLY IMPORTANT DIFFERENCE; PSORIASIS VULGARIS; TREATMENT RESPONSE;

EID: 84925845889     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/j.ad.2014.10.001     Document Type: Article

References (26)

1. J.E. Gudjonsson, and J.T. Elder Psoriasis: epidemiology Clin Dermatol 25 2007 535 546
2. S.R. Rapp, S.R. Feldman, M.L. Exum, A.B. Fleischer Jr.; and D.M. Reboussin Psoriasis causes as much disability as other major medical diseases J Am Acad Dermatol 41 1999 401 407
3. J.E. Gudjonsson, A. Johnston, and C.N. Ellis Novel systemic drugs under investigation for the treatment of psoriasis J Am Acad Dermatol 67 2012 139 147
4. T. Fredriksson, and U. Pettersson Severe psoriasis - oral therapy with a new retinoid Dermatologica 157 1978 238 244
5. S.R. Feldman, and G.G. Krueger Psoriasis assessment tools in clinical trials Ann Rheum Dis 64 2005 65 68
6. U. Mrowietz, K. Kragballe, K. Reich, P. Spuls, C.E. Griffiths, and A. Nast Definition of treatment goals for moderate to severe psoriasis: a European consensus Arch Dermatol Res 303 2011 1 10
7. C.S. Carlin, S.R. Feldman, J.G. Krueger, A. Menter, and G.G. Krueger A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis J Am Acad Dermatol 50 2004 859 866
8. J. Barker, M. Hoffmann, G. Wozel, J.P. Ortonne, H. Zheng, and H. van Hoogstraten Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1) Br J Dermatol 165 2011 1109 1117
9. J.H. Saurat, G. Stingl, L. Dubertret, K. Papp, R.G. Langley, and J.P. Ortonne Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) Br J Dermatol 158 2008 558 566
10. K. Reich, A.D. Burden, J.N. Eaton, and N.S. Hawkins Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials Br J Dermatol 166 2012 179 188
11. C. Leonardi, A. Menter, T. Hamilton, I. Caro, B. Xing, and A.B. Gottlieb Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis Br J Dermatol 158 2008 1107 1116
12. L. Puig, A. López, E. Vilarrasa, and I. García Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points J Eur Acad Dermatol Venereol 2013 Aug 19 10.1111/jdv.12238 [Epub ahead of print]
13. K. Reich, F.O. Nestle, K. Papp, J.P. Ortonne, R. Evans, and C. Guzzo Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial Lancet 366 2005 1367 1374
14. K. Gordon, K. Papp, Y. Poulin, Y. Gu, S. Rozzo, and E.H. Sasso Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL J Am Acad Dermatol 66 2012 241 251
15. A.B. Kimball, K.A. Papp, Y. Wasfi, D. Chan, R. Bissonnette, and H. Sofen Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study J Eur Acad Dermatol Venereol 27 2013 1535 1545
16. K.A. Papp, C. Leonardi, A. Menter, J.P. Ortonne, J.G. Krueger, and G. Kricorian Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis N Engl J Med 366 2012 1181 1189
17. Papp KA, Leonardi C, Menter A. Results after 48 weeks of Brodalumab (AMG 827) in subjects with moderate to severe plaque psoriasis in an open-label extension study. Abstract presented at the 2012 Annual Meeting of the European Academy of Dermatology & Venereology. Abstract FC02.4.
18. C. Leonardi, R. Matheson, C. Zachariae, G. Cameron, L. Li, and E. Edson-Heredia Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis N Engl J Med 366 2012 1190 1199
19. K. Gordon, C. Leonardi, D. Braun, G. Cameron, J. Erickson, and M. Lebwohl Results after at least 52 weeks of open label treatment with ixekizumab, an anti-IL-17A monoclonal antibody, in a phase 2 study in chronic plaque psoriasis J Am Acad Dermatol 70 2014 AB183
20. K.A. Papp, R.G. Langley, B. Sigurgeirsson, M. Abe, D.R. Baker, and P. Konno Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study Br J Dermatol 168 2013 412 421
21. R.G. Langley, B.E. Elewski, M. Lebwohl, K. Reich, C.E. Griffiths, and K. Papp Secukinumab in plaque psoriasis-results of two phase 3 trials N Engl J Med 371 2014 326 338
22. European Medicines Agency. Evaluation of medicines for human use. Clinical investigation of medicinal products indicated for the treatment of psoriasis. CPMP/EWP/2454/02. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003329.pdf.
23. P.L. Mattei, K.C. Corey, and A.B. Kimball Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies J Eur Acad Dermatol Venereol 28 2014 333 337
24. L. Melilli, R. Shikiar, and C. Thompson Minimum clinically important difference in Dermatology Life Quality Index in moderate to severe plaque psoriasis patients treated with adalimumab J Am Acad Dermatol 54 2006 AB 221 (P2894)
25. D.A. Revicki, M.K. Willian, A. Menter, J.H. Saurat, N. Harnam, and M. Kaul Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis Dermatology 216 2008 260 270
26. A. Chiricozzi, and J.G. Krueger IL-17 targeted therapies for psoriasis Expert Opin Investig Drugs 22 2013 993 1005